In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Piedmont Pharmaceuticals, LLC

Latest From Piedmont Pharmaceuticals, LLC

Can real world data talk to the money?

Over the past couple of years, real-world data (RWD) and real-world evidence (RWE) have emerged as key buzzwords along with big data, and we are set to hear even more of them, according to Richard Barker, director of the Centre for the Advancement of Sustainable Medical Innovation. Real-world studies (RWSs) are now becoming more common, but examples of their use and influence on reimbursement decisions or guidelines remain few and far between. Nevertheless, with their ability to demonstrate that a new intervention does work, after randomized controlled trials (RCTs) have shown that it can work, their use is growing, albeit in a fragmented and disconnected manner. These issues, along with other challenges relating to the use of RWD, were discussed at the eyeforpharma Real World Data Europe conference in London on 28–29 April 2014.

Neurology Spain

Market Insight - Alliances boost drug delivery as M&A and financing stall

Activity in the drug delivery sector has been geared towards alliances in 2009, says Phil Greenfield.

Gastrointestinal Metabolic Disorders

Commentary: Private investment round-up for April 2009

Investments in private pharmaceutical and biotech companies slumped by 24% in April, with the market being once again dominated by US companies, a Scrip analysis has found.

Respiratory Germany

PPD buys Magen BioSciences and sells anticancer research centre

PPD will expand into the dermatology market and move away from preclinical oncology research in a realignment towards its core operations.

Dermatology Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals